Dolutegravir sodium loaded solid lipid nanoparticles: A vaginal drug delivery system for pre-exposure prophylaxis of HIV

The objective of this study was to formulate dolutegravir sodium an antiretroviral drug into topical(vaginal) semisolid solid lipid nanoparticle gel formulation using a rapid, economical one step process. Solid lipidnanoparticles formulations were prepared using solvent injection method combined with sonication, using differenttype of lipids (e.g. Phospholipon 80H, Phospholipon 90H and Soy lecithin) and surfactants (Poloxamer 407,Poloxamer 188, and Tween 80). The SLN gel was formed in one step process using poloxamer 407 & water formingaqueous phase and stearic acid & phospholipon 80H in ethanol forming lipid phase. The lipid phase was injected into aqueous phase forming a creamy gel at 70⁰ C. Hence it does not require any gelling agent. It was optimized using a systematic approach of design of experiments. The formulation was evaluated for particle size, polydispersity index, zeta potential, flux, entrapment efficiency and results were found to be 455 nm, 0.411, -26.6 mV, 43.7±-0.12 µg/cm2/hr, 76.2% respectively. Drug release studies were conducted using two membranes via; dialysis membrane and goat vaginal tissue. The release pattern of the drug followed first order kinetics with Higuchi release mechanism. The release exponent ‘n’ of the Korsemeyer equation indicates the Fickian diffusional drug release. The ex vivo vaginal study of F2 formulation showed 64.89% of tissue deposition, which was 16 times more than the pure drug. This study concluded that the dolutegravir sodium, a sustained release solid lipid nanoparticle gel may have increased vaginaldeposition and might show site targeted effect.

PDF

___

[1] Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment and prevention. Lancet. 2014; 384(9939): 258-271. [CrossRef]
[2] Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of “me-too” HIV1 integrase inhibitors. Retrovirology. 2009; 6: 25. [CrossRef]
[3] Kobayashi M, Yoshinaga T, Seki T, wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011; 55(2): 813-821. [CrossRef]
[4] Siafaka PI, Üstündağ Okur N, Karavas E, Bikiaris DN. Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses. Int J Mol Sci. 2016; 17(9): E1440. [CrossRef]
[5] Das S, Chandhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharmscitech. 2011; 12(1): 62-76. [CrossRef]
[6] Freitas C, Müller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999; 47(2): 125-132. [CrossRef]
[7] Loo Ch, Basari M, Ismail R, Lau H, Tejo B, Kanthimathi M, Hassan H, Choo Y. Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int J Nanomedicine. 2013; 8: 13-22. [CrossRef]
[8] Fakhari A, Corcoran M, Schwarz A. Thermogelling properties of purified poloxamer 407. Heliyon. 2017; 3(8): e00390. [CrossRef]
[9] El-Housiny, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor:formulation and clinical study. Drug Deliv. 2018; 25(1): 2015. [CrossRef]
[10] Khalil RM, El-Bary AA, Kassem MA, Ghorab MM, Ahmed MB. Solid lipid nanoparticles for topical delivery of meloxicam: development and in vitro characterization. 1st Annual International Interdisciplinary Conference, AIIC 2013; 779-798.
[11] Khare A, Singh I, Pawar P, Grover K. Design and Evaluation of Voriconazole Loaded Solid Lipid Nanoparticles for Ophthalmic Application. J Drug Deliv. 2016; 6590361. [CrossRef]
[12] Ekambaram P, Abdul HS. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm. 2011; 3(3): 216-220. [CrossRef]
[13] Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK, Singh S. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Biomed Res Int. 2013; 584549. [CrossRef]
[14] Mirza MA, Panda AK, Asif S, Verma D, Talegaonkar S, Manzoor N, Khan A, Ahmed FJ, Dudeja M, Iqbal Z. A vaginal drug delivery model. Drug Delivery. 2016; 23(8): 3123-3134. [CrossRef]
[15] Radha GV, et al. Design and evaluation of topical vaginal proniosomal formulations of tenofovir disoproxil fumarate for HIV prevention. Int Res J Pharm. 2019; 10(2): 94-102.
[16] Madan J, Khude P, Dua K. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int J Pharm Invest. 2014; 4(2): 60-64.
[17] Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chem Pharm Bull. 2010; 58(5): 650-655. [CrossRef]
[18] Lakshmi PK, Sreekanth J, Sridharan A. Formulation development of fast releasing oral thin films of levocetrizine dihydrochloride with Eudragit® Epo and optimization through Taguchi orthogonal experimental design. Asian J Pharm. 2011; 5: 84-92
[19] Lakshmi PK, Thangellapalli N, Chennuri A, Prasanthi D, Veeresh B. Wound healing activity of topical lawsone gel on rat model. Int J Pharm Sci Res. 2017; 8(7): 3162-3169.
[20] Rao K, Vijaybhaskar D, Pratima S. Formulation of topical oral gel for the treatment of oral sub mucous fibrosis (OSMF). Der Pharm Lett. 2011; 3(1): 103-112.
[21] Lu PJ, Fu WE, Huang SC, Lin CY, Ho ML, Chen YP, Cheng HF. Methodology for sample preparation and size measurement of commercial ZnO nanoparticles. J Food Drug Anal. 2018; 26(2): 628-636. [CrossRef]
[22] Üstündağ-Okur N, Yurdasiper A, Gündoğdu E, Gökçe EH. Modification of solid lipid nanoparticles loaded with nebivolol hydrochloride for improvement of oral bioavailability in treatment of hypertension: polyethylene glycol versus chitosan oligosaccharide lactate. J Microencapsul. 2016; 33(1): 30-42. [CrossRef]
[23] Soma D, et al. Solid lipid nanoparticles of irbesartan: preparation, characterization, optimization and pharmacokinetic studies. Braz J Pharm Sci. 2017; 53(1): e15012. [CrossRef]
[24] Deshkar SS, Patil AT. Development of mucoadhesive gel of fluconazole for vaginal candidiasis. Indo Am J Pharm Res. 2015; 5(11): 3599-3610.
[25] Berginc K, Skalko-Basnet N, Basnet P, Kristl A. Development and evaluation of an in vitro vaginal model for assessment of drug´s biopharmaceutical properties: curcumin. AAPS PharmSciTech. 2012; 13(4): 1045-1053. [CrossRef]
[26] Abdel-Mottaleb M, Mortada N, Elshamy AA, Awad GAS. Preparation And Evaluation Of Fluconazole Gels. Egypt J Biomed Sci. 2007; 23(1): 266-286. [CrossRef]